Media Library

When it comes to orphan and paediatric medicines, a collaborative approach is essential.

A smart and future-proof framework can foster innovation in the EU while ensuring faster and widespread access to medicines.

The EU has an opportunity to ensure that we create a predictable and robust framework that leads to more investments and treatments for patients.

While everyone agrees that better access to medicines is important, the challenge with using the regulatory framework to achieve this objective is that it's not the right tool for the task.

View of the Novartis logo through the colorful facade of Forum 3, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building, Novartis Campus Basel (horizontal)

Close up of the Novartis logo on the Banting 1 building, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building from Park South, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building from the main gate, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building, Novartis Campus Basel (vertical)

Long-term assessment of the efficacy and safety of inclisiran in patients with high risk of cardiovascular events